Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients (SWIVEL)
The 'SWIVEL' Study (Switch Vs Effects Relief): Effectiveness of a Medication 'Switch' vs Guideline-Directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Sponsor: Dartmouth-Hitchcock Medical Center
Listed as NCT07071038, this PHASE2 trial focuses on Adjuvant Treatment and Breast Cancer and remains actively recruiting participants. Sponsored by Dartmouth-Hitchcock Medical Center, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .